NCT03449342 - Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 25, 2019

Study Completion Date

April 22, 2019

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa

Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)

Trial Locations (9)

70014

Novo Nordisk Investigational Site, Kolkata

110029

Novo Nordisk Investigational Site, New Dehli

Novo Nordisk Investigational Site, New Delhi

141008

Novo Nordisk Investigational Site, Ludhiana

400012

Novo Nordisk Investigational Site, Mumbai

411004

Novo Nordisk Investigational Site, Pune

560034

Novo Nordisk Investigational Site, Bangalore

632004

Novo Nordisk Investigational Site, Vellore

682041

Novo Nordisk Investigational Site, Kochi